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5 Key Points 
• A systematic literature review identified nine CER methods guidance documents. 
• These documents present more than three hundred individual methods 
recommendations, covering topics such as study design, bias, and statistical 
analysis. 
• Categories of shared methods recommendations were assembled which 
embodies a consensus of recommendations for CER methods.  
• All nine documents recommended transparency and adaptation for relevant 
stakeholders in the interpretation and dissemination of results. 
• Other shared recommendations identified in at least seven documents included 
transparent operational definitions allowing for replication, assessment of data 
and study measure validity, inclusion of clinically meaningful and objectively 
measured outcomes, and focusing on gap in knowledge that are relevant for 
decision-makers. 
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Abstract  
Purpose: Due to an increasing demand for quality comparative effectiveness research 
(CER), methods guidance documents have been published, such as those from the 
Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered 
Outcomes Research Institute (PCORI). Our objective was to identify CER methods 
guidance documents and compare them to produce a summary of important 
recommendations which could serve as a consensus of CER method recommendations.  
Methods: We conducted a systematic literature review to identify CER methods 
guidance documents published through 2014. Identified documents were analyzed for 
methods guidance recommendations. Individual recommendations were categorized to 
determine the degree of overlap. 
Results: We identified nine methods guidance documents, which contained a total of 
312 recommendations, 97% of which were present in two or more documents. All nine 
documents recommended transparency and adaptation for relevant stakeholders in the 
interpretation and dissemination of results. Other frequently shared CER methods 
recommendations included: study design and operational definitions should be 
developed a priori and allow for replication (n=8 documents); focus on areas with gaps in 
current clinical knowledge that are relevant to decision-makers (n=7); validity of 
measures, instruments, and data should be assessed and discussed (n=7); outcomes, 
including benefits and harms, should be clinically meaningful, and objectively measured 
(n=7). Assessment for and strategies to minimize bias (n=6 documents), confounding 
(n=6), and heterogeneity (n=4) were also commonly shared recommendations between 
documents. 
Conclusions: We offer a field-consensus guide based on nine CER methods guidance 
documents that will aid researchers in designing CER studies and applying CER 
methods.  
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Introduction  
 
As a result of an ever-increasing number of treatment options, real-world 
evidence is needed to inform clinical decision-making. Consequently, the demand for 
high-quality comparative effectiveness research (CER) has increased over the past 
several years. The Institute of Medicine has defined CER as, “the generation and 
synthesis of evidence that compares the benefits and harms of alternative methods to 
prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of 
care".1 Inherent in this definition is the head-to-head comparison of treatment 
approaches used in clinical practice to provide information on which treatments work 
best, for whom, and in which situations. To comparatively evaluate treatments, a wide 
range of methods and various study designs, including randomized controlled trials and 
observational studies, are utilized.   
In response to a number of recent CER funding initiatives based in the United 
States, under the 2009 American Recovery and Reinvestment Act and the 2010 Patient 
Protection and Affordable Care Act, which established the Patient-Centered Outcomes 
Research Institute (PCORI), several methods guidance documents have been 
developed recently.2-5 Despite the utility of such guides, it remains unclear which 
documents should be followed and under which circumstances, as consensus between 
the guidance documents has not been determined. To this end, this review sought to 
identify CER methods guidance documents, and then identify areas of agreement 
among CER methods recommendations to create a consensus document that may 
assist in the design and conduct of high-quality CER, including observational studies and 
randomized clinical trials (RCTs).  
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Methods 
 A literature search was conducted in February 2015 by two independent 
reviewers (JM, RM) to identify CER methods guides that included specific 
methodological recommendations for the design and conduct of CER. To identify 
published, peer-reviewed literature, Pubmed's Medical Subject Heading (MeSH) system 
and the query “comparative effectiveness research/methods” was used.6 To find 
documents that were not published in the peer-reviewed literature, such as industry 
reports and white papers, grey literature search methods were employed.7-9 Specifically, 
we used the query "comparative effectiveness research" in Google and Google Scholar. 
Websites of organizations involved in CER, including the Agency for Healthcare 
Research and Quality (AHRQ), European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance (ENCePP), PCORI, Food and Drug 
Administration, Health Canada, and National Institute for Health, were also searched. 
While CER is a newer term to describe an existing discipline that has carried various 
names, the focus of our search for methods guidelines was specific to this term that was 
popularized by the American Reinvestment and Recovery Act. 
 A search result title was assessed for relevance to CER methods by the inclusion 
of specific words, including "methods," "methodology," "standards," "conducting," 
"guidelines," and "practices". Subsequently, the abstracts from the results with relevant 
titles were reviewed. The following information was collected from each abstract: 
author(s), year of publication, and affiliations. Each abstract was categorized as a CER 
overview, a presentation of specific analytic methods, or a study of a specific therapeutic 
topic. Only full-text documents categorized as a CER overview were obtained and 
analyzed for potential inclusion as a CER methods guidance document. Any document 
not consisting of a set of formal recommendations on CER methods, or those related to 
meta-analyses or systematic reviews, were excluded. Guidance documents released as 
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part of a series or an update were included together as a single guide. Documents 
published through December 2014 were included in our review. 
All recommendations regarding CER methods were extracted from each 
guidance document by two independent reviewers (JM, RM). The content of each 
statement was assessed to determine whether the statement provided guidance for 
conducting CER, and therefore should be considered a CER recommendation. 
Statements not meeting this criterion were excluded. The list of included 
recommendations were agreed upon by both reviewers and an additional author (AC).  
 
Results 
We reviewed 1,819 Pubmed search results and 360 grey literature results, and 
identified 248 documents with titles relevant to CER methods. Documents related to a 
specific therapeutic area (Pubmed n=32, 19.9%; grey n=7, 8.1%) or a specific 
methodology (Pubmed n=64, 39.8%; grey n=34, 39.1%) were excluded, while CER 
overviews (Pubmed n=65, 40.4%; grey n=46, 52.9%) were reviewed for inclusion. From 
this pool of CER overviews, nine CER methods guidance documents were identified, of 
which five were already known to the authors (Figure 1, Table 1). These nine documents 
were published between 2009 and 2014. Organizations authored seven of the nine 
documents, and individual authors wrote the remaining two.  
Following the exclusion of statements not meeting the criterion of a CER 
methods recommendation and splitting statements with multiple recommendations into 
individual recommendations, there were 312 recommendations. After reviewing all 
recommendations, 15 categories of shared recommendations were created by two of the 
authors (JM, AC). All recommendations were then reviewed and placed in a 
corresponding category or categories, as some recommendations fell in to more than 
one category. The number of documents with recommendations in each of the 
8 
 
categories were totaled. Specific recommendations within categories of shared 
recommendations were reviewed in greater detail to identify common themes which 
were also summed between documents. While the categorization of the 
recommendations was completed by two authors (JM, AC), all of the authors reviewed 
and approved these categorizations. Recommendations that did not correspond with any 
of the 15 categories were considered non-shared recommendations.  
Only one shared recommendation category was identified across all nine CER 
documents, suggesting that the interpretation and dissemination of CER study results 
should be transparent and adapted for relevant stakeholders (Table 2). Other frequently 
shared CER methods recommendations included: study design and operational 
definitions developed a priori and transparent enough to allow for replication (n=8 
documents, 89%); focus on areas with gaps in current clinical knowledge that are 
relevant to decision-makers (n=7, 78%); assess and discuss validity of measures, 
instruments, and data, including data collection (n=7, 78%); outcomes, including benefits 
and harms, should be clinically meaningful, and objectively measured (n=7, 78%); 
appropriateness of exposures and interventions should be assessed and described 
(n=6, 67%).  
Assessment for and strategies to minimize bias (n=6 documents), confounding 
(n=6), and heterogeneity (n=4) were also commonly shared recommendations between 
documents. Other shared recommendations supported rigorous literature review to 
guide study design and planning (n=6, 67%), use of sensitivity analyses (n=5, 56%), 
involving relevant stakeholders (n=5, 56%), use of appropriate statistical techniques 
(n=5, 56%), following ethical requirements (n=4, 44%), and improving health care value 
(n=2, 22%). There were nine individual non-shared recommendations (3% of all 
recommendations) in five of the nine documents which did not fall in to one of the shared 
recommendation categories, including protection of the independence of peer review5, 
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time and costs considerations as secondary objectives are defined10, and separation of 
feasibility studies from the main study results.10  
 
Discussion  
This study provides a synthesis of CER methods guidance documents for the 
purpose of informing decisions on the development and conduct of quality CER 
research. This consensus document identifies the most commonly shared expectations 
of quality CER from an interdisciplinary standpoint, incorporating recommendations from 
experts in academia, industry, professional societies, and regulatory agencies. Our study 
identified nine documents with over 300 recommendations for designing and conducting 
CER. We were able to identify the most frequently shared recommendations which can 
serve as a summary resource for researchers as they design and implement CER 
studies.  
The documents had varying approaches to recommending specific CER 
methods. For instance, the Patient-Centered Outcomes Research Institute (PCORI), 
Agency for Healthcare Research and Quality (AHRQ), and European Network of 
Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) present detailed 
methodological guidance, organized by topic area, which can serve as a how-to guide 
for researchers attempting to design and conduct CER.4, 5, 10 In contrast, the American 
Medical Association (AMA) and American Heart Association (AHA) documents provide 
less information about study design and analysis and more about health policy, research 
dissemination, and general principles to guide researchers.11, 12 Despite their varying 
perspectives, the documents are unified in their call for the development of CER 
methods standards. By compiling a list of frequently agreed upon CER methods 
recommendations, we have facilitated the application of these recommendations for 
developing CER research based on expert recommendations.  
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From our list of shared recommendations, it is apparent that some of the most 
important aspects of quality CER include adaptation of the interpretation and 
dissemination of study results for patients, providers, and payers; interpretation of study 
limitation in the context of the population studied; development of a priori study 
protocols; evaluation of missing data and measure validity; use of clinically meaningful 
endpoints; use of appropriate measures of exposure and statistical techniques, including 
sensitivity analyses; assessing and minimizing bias, including misclassification and 
immortal time bias, confounding, including residual confounding, and heterogeneity; and 
involvement of relevant stakeholders while following ethical requirements. While a study 
may adhere to sound CER methodology, the ability to assess the study’s quality is 
severely limited if it does not report sufficient amounts of information. The results of our 
study support transparency in the protocol and manuscript development process. 
Furthermore, transparency in statistical analysis is stressed in CER, allowing for not only 
public critique of methodology, but also study reproducibility.  
  The synthesis of these nine documents demonstrated a large degree of overlap, 
as over 97% of individual recommendations were found in at least two documents. 
Though the documents themselves were not specifically reviewed for contradictions, no 
contradictions were noted in the extracted recommendations. Additionally, while 
individual documents may have primary areas of focus for conducting CER, the high 
degree of overlap suggests a general sense of agreement among the nine documents 
regarding the most important topics. Though a number of these topics are not exclusive 
to CER, and may be applied more broadly to pharmacoepidemiology and outcomes 
research, the emphasis placed on these recommendations by CER experts highlights 
their importance for CER, particularly when considering how CER contributes to clinical 
decision-making.13   
It should be noted that our consensus guide, summarizing key CER methods 
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recommendations, may be useful in the development of detailed, high-quality, 
transparent CER that optimizes clinical applicability but does not replace the guidance 
provided by the individual documents identified. While the concept of consensus as a 
scientific theory has been controversial in the past, our goal was to present a summary 
of the overlap between the 312 recommendations from the nine CER methods guidance 
documents.14 For specific guidance and additional CER resources, the reader is directed 
to the individual documents. Now that a consensus of recommendations has been 
identified, it will be important to identify whether consensus exists for how these 
recommendations should be implemented and accomplished. 
While some recommendations extracted from the guides focus on the reporting 
of CER studies, they were interpreted as recommendations for the design and conduct 
for CER. For example, while reporting of limitations and confounders is not necessarily 
part of conducting research activities, it is an important step in promoting study 
transparency. With consistent transparency throughout the study process, study quality 
is improved. Furthermore, in the context of design, confounders and limitations should 
be considered a priori, so that approaches to minimize confounding and limitations can 
be implemented in the design phase.4, 5 One such strategy includes sensitivity analyses, 
as “residual confounding should be assessed, and approaches to estimating its effect, 
including sensitivity analyses, should be included.” 4, 15 The utility of sensitivity analyses 
is also supported by a recent study which identified sensitivity analyses as the single 
best predictor of quality for studies published in higher-impact journals.16 The effect of 
missing data as a potential limitation must also be assessed thoroughly.4, 15, 17  
The goal of this project was to identify areas of agreement among CER methods 
recommendations to assist in the design and conduct of high-quality CER. Many of the 
recommendations were focused specifically on observational research, rather than 
RCTs.  This focus may be a result of the existing clinical trial methods guidance 
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documents, including guidance from the Food and Drug Administration on Good Clinical 
Practice and Clinical Trials and the Pragmatic-Explanatory Continuum Indicator 
Summary (PRECIS). 18, 19  Several other documents that may be useful in the design and 
conduct of CER are those specifically focused on reporting of research results, including 
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
Statement, the GRACE Checklist, and the Consolidated Standards of Reporting Trials 
(CONSORT) Statement and Checklist.20-22 STROBE and GRACE promote dissemination 
of quality observational study results, while CONSORT provides guidance specific to 
RCT reporting in order to assess study validity.20-22 While the aforementioned documents 
were not included in our analysis as they were either not specific to CER or focused on 
reporting rather than the design and conduct of CER, they are important resources, 
particularly for the reporting of and assessment of CER quality. Lastly, it is also 
necessary to acknowledge international efforts to improve the utilization of effectiveness 
research methods in clinical decision-making, including the GetReal project conducted 
by the Innovative Medicines Initiative (IMI) and the European Medicines Agency’s (EMA) 
Draft guidance for Post-Authorization Efficacy Studies (PAES).23,24  
 There were several limitations in the development of our consensus document. 
Firstly, selection of the documents utilized in our study was based upon specific search 
criteria. Thus, while our search returned an expansive list of articles for review, those 
documents that did not show up based on our search terminology were not included, 
such as the Guidelines for Good Pharmacoepidemiology Practices.25 We used specific 
and reproducible criteria for searching the published literature, however, most of the 
guidance documents were identified from the grey literature search. Second, it should be 
noted that the documents reviewed for consensus were the most up-to-date revisions at 
the time the literature search was conducted. As such, guidance documents regularly 
updated may have more recent versions, including the ENCePP Guide on 
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Methodological Standards in Pharmacoepidemiology (Revision 4).26 Lastly, the 
extraction and categorization of shared recommendations was subject to the 
interpretation of two independent reviewers. In cases of disagreement regarding the 
extraction or categorization of specific recommendations within a shared 
recommendation category, a third independent reviewer was used for the final 
determination. We also mitigated this limitation by having all authors review and approve 
the categorization of all recommendations.  
 
Conclusion  
We conducted a systematic literature review to develop a single guide of 
recommended CER methods, and identified nine CER methods guidance documents. 
The shared recommendations identified from this literature review emphasized adequate 
and transparent CER study planning and development using validated data, appropriate 
exposure measures, clinically meaningful and objectively measured outcomes, and 
statistical techniques which minimize bias and confounding. Further, CER should focus 
on areas that are relevant for decision-makers and adapt the interpretation and 
dissemination of results for key stakeholders. This overview of synthesized guidance 
may aid researchers and decision-makers in conducting and implementing quality 
comparative effectiveness research.   
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Figure 1. Methods guidance document inclusion  
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Table 1. CER methods guidance documents 
Document 
number 
Document title Authors Year Affiliation Methods 
recommen-
dations (N) 
Document 
source 
1 
The American Heart 
Association's Principles 
for Comparative 
Effectiveness 
Research12 
Gibbons et 
al. 2009 AHA 10 
Grey 
Literature 
2 
Good Research 
Practices for 
Comparative 
Effectiveness Research 
– Parts I,II,III15, 27, 28 
Berger et 
al.  
Cox et al. 
Johnson et 
al. 
2009 ISPOR 32 
Pubmed, 
Grey 
Literature 
3 
American Medical 
Association Principles 
for Comparative 
Effectiveness 
Research11 
AMA 2011 AMA 11 Grey Literature 
4 
Ten Commandments” 
for Conducting 
Comparative 
Effectiveness Research 
Using “Real-World 
Data17 
Willke RJ, 
Mullins D 2011 
Pfizer, 
University 
of 
Maryland 
13 Pubmed 
5 
Principles for Planning 
and Conducting 
Comparative 
Effectiveness 
Research29 
Luce et al. 2012 Various 13 Grey Literature 
6 
PCORI Methodology 
Standards / PCORI 
Methodology Report5 
PCORI 2013 PCORI 31 Grey Literature 
7 
Developing a Protocol 
for Observational 
Comparative 
Effectiveness 
Research4 
Velentgas 
et al. 2013 AHRQ 133 
Grey 
Literature 
8 
Guide on 
Methodological 
Standards in 
Pharmacoepidemiology 
(Revision 3)10 
ENCePP 2014 ENCePP 43 Grey Literature 
9 GRACE Principles21 Dreyer et al. 2014 GRACE 26 
Grey 
Literature 
AHA, American Heart Association; AHRQ, Agency for Healthcare and Research Quality; 
AMA, American Medical Association; ENCePP, European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance; GRACE, Good Research for 
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Comparative Effectiveness; ISPOR, International Society for Pharmacoeconomics and 
Outcomes Research; PCORI, Patient-Centered Outcomes Research Institute 
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Table 2. Categories of shared CER methods recommendations  
 
Shared CER Methods Recommendations Document 
Numbers* 
N (%)** 
Interpretation and dissemination of CER study results should be 
transparent and adapted for relevant stakeholders 
Interpret results in the context of the population studied 
Adapt presentation of results for different stakeholders 
Interpret results in the context of limitations 
1-9 9 (100) 
 
5 (56) 
4 (44) 
2 (22) 
CER study design and operational definitions should be developed a priori 
and be transparent to allow for replication 
Operational definitions should be included in the study protocol and 
deviation from protocol definitions should be described 
Present sufficient information to allow for replication 
1-4, 6-9 8 (89) 
 
5 (56) 
 
2 (22) 
CER should focus on areas with gaps in current clinical knowledge that are 
relevant to decision-makers 
1, 3-8 7 (78) 
Validity of measures, instruments, and data, including data collection 
methods, should be assessed and discussed 
2, 4-9 7 (78) 
Evaluate data validity 
Evaluate missing data 
 5 (56) 
4 (44) 
Outcomes, including benefits and harms, should be clinically meaningful, 
objectively measured, and transparently reported 
1, 4-9 7 (78) 
Outcomes should be clinically meaningful 
Outcomes should be objectively measured 
 4 (44) 
2 (22) 
Outcomes should be patient-centered  2 (22) 
Exposures and interventions should be adequately described and 
assessed for appropriateness 
2, 5-9 6 (67) 
Incident user design should be utilized if possible  2 (22) 
Assess for and implement strategies to minimize bias 2, 4-5, 7-9 6 (67) 
Minimize misclassification bias 
Studies should be free of immortal time bias 
 4 (44) 
3 (33) 
Assess for and implement strategies to mitigate confounding 2, 4, 6-9 6 (67) 
Assess for unmeasured, missing, or residual confounders  4 (44) 
Rigorous review of the literature should be performed to guide CER study 
design and planning 
1-3, 5, 7-8 6 (67) 
Review all relevant treatment approaches, including new treatments  4 (44) 
Consider sensitivity analyses, including changes in the exposure, 
outcome, confounder, or covariate definitions or classifications 
2, 6-9 5 (56) 
Relevant stakeholders should be involved in the planning and conduct of 
CER 
3, 5-8 5 (56) 
Utilize appropriate statistical techniques, defined a priori in a statistical 
analysis plan, according to study design and endpoints 
Develop a comprehensive statistical analysis plan prior to study initiation 
Present statistical assumptions  
Describe the statistical modelling approach 
2, 4, 6-8 5 (56) 
 
3 (33) 
3 (33) 
3 (33) 
CER should follow ethical requirements and conflicts of interest should be 
fully disclosed 
3-4, 7-8 4 (44) 
Assess for and report heterogeneity 4, 6-8 4 (44) 
CER should focus on improving health care value 1, 3 2 (22) 
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*Column values correspond to document number in Table 1. 
** N (%) of guidance documents which include the specific recommendation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
